Results obtained with the NIVGRIP inactivated influenza vaccine applicable by nasal and/or oral route.
The NIVGRIP inactivated influenza vaccine prepared in the "Stefan S. Nicolau" Institute of Virology has proved its efficacy in the specific prophylaxis of influenza. The vaccine can be administered by nasal and/or oral route and has a very low reactogenicity. Application of the NIVGRIP vaccine results in seroconversion rates of 50-70% and in rises in the levels of local neutralizing antibodies in 75-80% of the vaccines. Numerous epidemiological surveys have ascertained that the protection rate obtained by nasal administration of the NIVGRIP vaccine ranges from 50 to 90%, being comparable with that of other commercially available vaccines. The advantages of the use of an inactivated, whole virus vaccine applicable by nonparenteral routes are discussed.
D000281:Administration, Intranasal; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000096:biosynthesis; D002648:Child; D002675:Child, Preschool; D006801:Humans; D007223:Infant; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007251:Influenza, Human / Q000382:microbiology / Q000517:prevention & control*; D008875:Middle Aged; D012140:Respiratory Tract Diseases / Q000382:microbiology; D014611:Vaccination
D000914:Antibodies, Viral; D007252:Influenza Vaccines